These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. You IC; Kang IS; Lee SH; Yoon KC Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596 [TBL] [Abstract][Full Text] [Related]
5. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty. Foroutan A; Fariba B; Pejman B; Mahmoud J; Khalil GF; Arash EA; Foroutan P Cornea; 2010 Nov; 29(11):1268-72. PubMed ID: 20802316 [TBL] [Abstract][Full Text] [Related]
12. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570 [TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Kim TI; Kim SW; Kim S; Kim T; Kim EK Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]